Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure
NCT ID: NCT05586048
Last Updated: 2023-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1200 participants
OBSERVATIONAL
2023-04-01
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction
NCT04695990
Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
NCT01555320
Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
NCT01612260
Evaluating the Safety and Efficacy of Qishen Granules Among Patients With Chronic Heart Failure
NCT03027375
The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula
NCT06686355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposed group
patients who received YQFM
Yiqi Fumai Lyophilized Injection(YQFM)
No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
Non-exposed group
patients who didn't receive YQFM
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yiqi Fumai Lyophilized Injection(YQFM)
No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ageā„18 years
* Voluntarily participate in and sign the informed consent form
Exclusion Criteria
* Known allergies to drugs or drug ingredients
* Patients enrolled in other trials within 1 month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Natural Science Foundation of China
OTHER_GOV
China Academy of Chinese Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yan Liu, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xuecheng Zhang, MD
Role: STUDY_DIRECTOR
Dongzhimen Hospital, Beijing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongzhimen Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang
Guiyang, Guizhou, China
The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Guiyang, Guizhou, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhenghuan Li
Role: primary
Tao Xv
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Zhang J, Sun Y, Zhou K, Zhang X, Chen Y, Hu J, Zhong C, Liu Y, Shang H. Rationale and design of the AUGUST-AHF Study. ESC Heart Fail. 2020 Oct;7(5):3124-3133. doi: 10.1002/ehf2.12787. Epub 2020 Jun 22.
Zhang X, Kang J, Zhang J, Chen Y, Dai H, Hu M, Liu Y, Shang H. Effectiveness of Yiqi Fumai lyophilized injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study. Front Cardiovasc Med. 2023 Jan 10;9:1074406. doi: 10.3389/fcvm.2022.1074406. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUGUST-AHF cohort
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.